vision sciences inc .
vision - sciences inc. ; vision - sciences, inc. announces new executive vice - president and chief financial officer
vision - sciences, inc. tne system offers solution for sedation concerns | biospace
vision - sciences, inc. ron hadani, ceo 845 - 365 - 0600
vision - sciences inc. ; vision - sciences, inc. announces new executive vice - president and chief financial officer - abn newswire (@ abn _ newswire )
vision - sciences, inc. announces new executive vice - president and chief financial officer
... - for - stock merger of pell’s vision - sciences inc. and rob kill’s uroplasty inc. after the merger ...
contact: vision - sciences, inc. christian escobar, marketing manager 845 - 365 - 0600
vision - sciences owns the registered trademarks vision sciences®, endosheath®, endowipe®, slide - on®, and the vision system® .
vision - sciences, inc. announces new executive vice - president and chief financial officer nasdaq: vsci
vision - sciences, inc. announces election of new director - business - press releases | nbc news
... inc. and vision - sciences inc. as a result of which the former uroplasty stockholders held 62. 5 percent of ...
vision‑sciences owns the registered trademarks vision sciences ®, slide - on ®, endosheath ® and the vision system ®. information about vision - sciences' products is available at urltoken .
contact: vision - sciences, inc. ron hadani, ceo + 1 - 845 - 365 - 0600
vision - sciences, inc. receives ce clearance and health canada approval to market its video - based advanced endoscopy lines
contact: vision - sciences, inc. katherine wolf, cfo & evp, corporate development (845) 365 - 0600
... achieve those goals. the drama stems from the march 2015 merger of pell’s vision - sciences inc ...
, vision - sciences, inc. designs, develops, manufactures and markets products for flexible endoscopy. the company' s unique product lines feature a streamlined visualization system and proprietary sterile disposable microbial barrier, known as endosheath technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. for more information on vision - sciences and its products, please visit vision - sciences, inc. at
terms of service | privacy policy | © 2018 crunchbase inc. all rights reserved .
signature mapping medical sciences, inc. (smms) is a wholly - owned subsidiary focused on the development of computer vision automated medical diagnostic and decision support software solutions .
in connection with the proposed merger, vision - sciences plans to file with the sec a registration statement on form s - 4 that will include a joint proxy statement of uroplasty and vision - sciences that also constitutes a prospectus of vision - sciences. uroplasty and vision - sciences will make the joint proxy statement / prospectus available to their respective shareholders .
vision - sciences, inc. (nasdaq: vsci) develops, manufactures and markets unique flexible endoscopic products for a variety of markets. for more information, please visit us at urltoken
vision - sciences, inc. (nasdaq: vsci) develops, manufactures and markets unique flexible endoscopic products for a variety of markets. for more information, please visit us at urltoken
vision - sciences, inc. designs, develops, manufactures and markets products for flexible endoscopy. the company' s unique product lines feature a streamlined visualization system and proprietary sterile, disposable microbial barrier, known as endosheath® technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. information about vision - sciences' products is available at urltoken .
by internet: under the
investors
tabs at the uroplasty website at urltoken and vision - sciences website at urltoken .
orangeburg, n. y. , dec. 15, 2010 (globe newswire) - - vision - sciences, inc. , (nasdaq: vsci) (vision - sciences), announced today that its board of directors elected dr. bruce polsky to serve as a member of its board, effective immediately. dr. polsky will be an independent member of the board .
orangeburg, n. y. , june 3, 2008 (prime newswire) - - vision - sciences, inc. , (nasdaq: vsci) (
vision - sciences
), announced today that it received approval from underwriters laboratories inc. to affix the ce mark to its new line of advanced digital, video - based flexible endoscopes, which come with an integrated
built - in
light source, eliminating the need for a separate camera head, light cable and optical coupler. vision - sciences also announced health canada approval for these scopes. with health canada' s approval, and the approval of applicable technical files and updated ec certificates, vision - sciences is now permitted to distribute and sell its scopes throughout all eu countries and canada .
, vision - sciences' chairman. these notes and warrants have been amended in connection with the merger, as described below .
vision sciences, a medical device company, develops flexible endoscopes as a control solution to decrease the risk of cross - contamination .
vision - sciences, inc. designs, develops, manufactures and markets unique flexible endoscopic products utilizing sterile disposable sheaths, the slide - on ® endosheath ® technology, which provide the users quick, efficient product turnover while ensuring the patient a contaminant - free product .
is acting as exclusive financial advisor to uroplasty. leerink partners is acting as exclusive financial advisor to vision - sciences. oppenheimer wolff & donnelly llp is acting as counsel for uroplasty, and royer cooper cohen braunfeld llc is acting as counsel for vision - sciences .
orangeburg, n. y. , sept. 16, 2008 (globe newswire) - - vision - sciences, inc. (nasdaq: vsci) today announced that katherine wolf has been named as the company' s executive vice - president, corporate development and chief financial officer, effective today. in this role she will be responsible for all of vision - sciences' financial operations and business development activities .
orangeburg, n. y. , sept. 16, 2008 (globe newswire) - - vision - sciences, inc. (nasdaq: vsci) today announced that katherine wolf has been named as the company' s executive vice - president, corporate development and chief financial officer, effective today. in this role she will be responsible for all of vision - sciences' financial operations and business development activities .
vision - sciences, inc. and its subsidiaries designs, develops, manufactures, and markets products for endoscopy - the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. our products are sold throughout the world
gilead sciences, inc. is a research - based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. we strive to transform and simplify care for people with life - threatening illnesses around the world .
vision - sciences, inc. (nasdaq: vsci) develops, manufactures and markets unique flexible endoscopic products for the urology, gastroenterology and the ent markets, utilizing the proprietary sterile disposable endosheath (r) technology. this technology provides quick and efficient equipment turnover, and ensures the patient a contaminant - free endoscope insertion .
i am excited to join a company with such great potential ,
said ms. wolf .
i think vision - sciences' technology and management creates a tremendous opportunity. i look forward to joining the rest of the team as we implement vision - sciences' financial, business development and operational strategies .
i am extremely pleased to welcome bruce to the board. his extensive medical background and knowledge of infectious diseases add significantly to our organization ,
said lewis pell, chairman of vision - sciences. dr. polsky was elected as a class ii director, to serve until vision - sciences' 2011 annual shareholders' meeting. dr. polsky was nominated to be reelected to the board at vision - sciences' annual shareholders' meeting, expected to be held in september 2011 .
copyright © 2014 applied visual sciences, all rights reserved. terms of use |
guardian technologies international, inc. (gdti) is a wholly - owned subsidiary focused on the development of automated target recognition software solutions for the homeland security and military marketplaces .
following the closing of the transaction, which is expected to occur during the first half of 2015, the combined company will conduct business as cogentix medical, inc. (nasdaq :
) and from uroplasty and vision - sciences. requests for copies of the joint proxy statement / prospectus and other documents filed by uroplasty with the sec may be made by contacting
, as well as both companies' subsequent quarterly reports on form 10 - q and other information filed by each company with the sec. uroplasty and vision - sciences caution investors not to place considerable reliance on the forward - looking statements contained in this press release. you are encouraged to read uroplasty' s and vision - sciences' filings with the sec, available at
the merger of uroplasty and vision - sciences will create a medical device company positioned for growth with proprietary, innovative technologies serving the urology market. in addition to the minimally - invasive urgent pc and macroplastique product lines, uroplasty' s 44 person u. s. sales organization, along with vision - sciences' 12 person u. s. sales organization, will aggressively market vision - sciences' proprietary endosheath technology platform. internationally, the combined company' s products will be sold through uroplasty' s eight direct sales representatives as well as the current distributors of both companies .
uroplasty, vision - sciences, their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from uroplasty' s and vision - sciences' respective shareholders in connection with the proposed transaction. information about the directors and executive officers of uroplasty and their ownership of uroplasty stock is set forth in uroplasty' s annual report on form 10 - k for the fiscal year ended
. these documents can be obtained free of charge from the sources indicated above. certain directors, executive officers and employees of uroplasty and vision - sciences may have direct or indirect interest in the transaction due to securities holdings, vesting of equity awards and rights to severance payments. additional information regarding the participants in the solicitation of uroplasty and vision - sciences shareholders will be included in the joint proxy statement / prospectus filed with the sec .
, 2015. once the existing uroplasty sales team is fully trained on the vision - sciences' product line, the new company is expected to achieve sustainable annual revenue growth of 15% beginning with its second fiscal year .
katherine has tremendous experience in healthcare investment banking and finance, which will be invaluable to vision - sciences as we continue to expand the applications for our technologies ,
said ron hadani, president and ceo of vision - sciences .
her background in capital markets, her reputation among the financial community and a deep understanding of our business make her uniquely qualified to help us expand on opportunities to capitalize on our revolutionary videoscope and other new technologies .
under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, each outstanding share of uroplasty' s common stock will be exchanged for 3. 6331 shares of vision - sciences' common stock. upon completion of the merger, uroplasty shareholders will own 62. 5% of the shares of the combined company on a fully - diluted basis, and vision - sciences shareholders will own 37. 5% . [ 1 ]
, who will become senior vice president of global sales and marketing. cogentix medical' s board of directors will be comprised of the five representatives from uroplasty' s existing board and three representatives from vision - sciences' existing board .
, for a discussion of these and other risks and uncertainties. the forward - looking statements in this press release speak only as of the date of this release, and uroplasty and vision - sciences undertake no obligation to update or revise any of these statements. uroplasty' s and vision - sciences' businesses are subject to substantial risks and uncertainties, including those referenced above. investors, potential investors, and others should give careful consideration to these risks and uncertainties .
, president and ceo of uroplasty .
we are confident that offering vision - sciences' urology product lines to our core urology customer base will also make us more meaningful and valuable to those customers. at the same time, we expect that the increased focus by care providers on endoscopic efficiency and prevention of cross - contamination creates significant growth opportunity for vision - sciences' endosheath technology in adjacent markets such as ent and pulmonology. with more than five million units sold and zero reported cases of cross contamination, we believe that endosheath products will be the standard of care for endoscopic applications, and our team fully intends to turn this efficacy leadership into market leadership. we look forward to working with the vision - sciences' team to enhance shareholder value through this combination .
vision - sciences' new digital scopes employ our proprietary endosheath (r) technology. unlike endoscopes from other manufacturers, vision - sciences' new advanced video scopes do not contain difficult - to - clean operating channels. instead, our video scopes utilize our patented, disposable, sterile slide - on (r) endosheath (r) technology which covers the entire endoscope. each disposable sheath contains a sterile operative channel, which eliminates patient tissue or organic matter from coming into contact with the reusable endoscope or the next patient .
dr. polsky commented ,
i am delighted to join the board of vision - sciences. i believe the company' s endosheath technology for flexible endoscopy is unique, providing sterile, efficient endoscopic procedures without the traditional complexities and difficulties associated with conventional endoscopy .
the named executive officers and directors of each company, representing approximately 4. 2% and 39. 1% of uroplasty' s and vision - sciences' outstanding common stock respectively, evidenced their support by entering into voting agreements to vote in favor of the transaction .
cogentix medical, inc. , formerly vision - sciences, inc. , is a medical device company. the company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, endosheath technology. the company produces and markets endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans - nasal esophagoscopy (tne) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (dpu). the company offers urgent pc neuromodulation system, a nerve stimulation device that delivers percutaneous tibial nerve stimulation (ptns) for the office - based treatment of overactive bladder (oab). it also offers macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. it markets additional bulking agents: ptq for the treatment of fecal incontinence and the vox for vocal cord augmentation .
orangeburg, n. y. , oct. 27, 2014 (globe newswire) - - the report by the new york city office of the chief medical examiner on the death of joan rivers points to a
predictable complication of medical therapy .
vision - sciences (nasdaq: vsci) believes one solution to these complications is a sedation - free exam for the patient. the vision sciences® tne endoscopy system with patented endosheath® technology offers physicians the ability to visualize, diagnose, and treat a patient' s upper airway, throat, esophagus, and stomach without the need for the complications of sedation .
we are very excited to be able to begin shipping orders to our european and canadian customers ,
stated ron hadani, president and chief executive officer vision - sciences .
we will now be able to meet the medical community' s overwhelming interest in our products, and expand our opportunities in the european and canadian markets .
a key necessity in stopping the growth of esophageal cancer is a safe, cost - effective, efficient diagnostic option for physicians ,
stated howard zauberman, president and chief executive officer of vision - sciences .
we believe our tne system combined with our endosheath technology provides the ideal instrument for the mounting need in diagnosing and managing esophageal disorders .
since joining vision - sciences in 2006, mr. yoav m. cohen has served as our chief financial officer and until april 2008, as our acting chief operating officer. mr. cohen is returning to nyc advisors, llc, a financial advisory firm located in white plains, new york, as its managing partner, and will continue to devote his time and substantial efforts working closely with us on accounting and financial projects .
yoav has provided outstanding support to vision - sciences, as we continue to grow ,
said mr. hadani .
under yoav' s leadership and guidance, we have updated and modernized our accounting, financial and operational systems, and we look forward to his continued contribution .
the vision - sciences innovative endoscopy technology and the transnasal approach avoid the use of propofol sedation, allowing patients to undergo the diagnostic exam while alert and awake. due to the small size of the tne system, the endoscope can be comfortably passed through the nasal passage instead of through the mouth, avoiding the patient gag reflex – a significant factor in the requirement for sedation in traditional oral exams .
, chairman of vision - sciences, commented ,
during the past several months as we have evaluated the combination of our two companies, we have been thoroughly impressed by uroplasty' s senior management team and distribution platform. they achieved notable growth with the urgent pc system, and we believe under uroplasty' s leadership, that our shareholders have the best opportunity to generate value through maximizing the global market potential for the combined company' s product lines and proprietary technology .
vision - sciences is currently the only provider of an fda - cleared line of transnasal endoscopes for this procedure that utilizes the patented endosheath technology, a cost - effective and safe solution for patients, doctors, hospitals, and other medical facilities. with endosheath technology, the tne endoscope is placed inside a new, sterile cover for each exam. the sheath is discarded after each procedure, guarding against the potential of an unclean endoscope and the risk of bacterial or viral cross - contamination with the next patient .
the transaction is expected to qualify as a tax free reorganization under the internal revenue code. the transaction is subject to customary closing conditions, including approval of the shareholders of each of uroplasty and vision - sciences. in connection with this transaction, the convertible promissory notes held by mr. pell will be amended. the maturity date of the amended notes will be five years from the date of the closing the merger, and interest accrued under the notes shall be calculated quarterly and payable on the maturity date or upon repayment or conversion of all or any portion of the principal. in addition, the notes will not be convertible until the third anniversary of the closing, except in a change in control or if the company decides to prepay the notes. vision - sciences and mr. pell also agreed to extend the period during which he may exercise his warrants, which will be exercisable starting on the third anniversary of the closing and ending on the later of the maturity date of the convertible promissory notes or the date on which the notes are converted or paid in full. the warrants would also be exercisable in the event of a change in control .
, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. uroplasty' s focus is the continued commercialization of its urgent® pc neuromodulation system, which uroplasty believes is the only commercially available, fda - cleared device that delivers percutaneous tibial nerve stimulation (ptns) for the office - based treatment of overactive bladder (oab). oab is a chronic condition that affects approximately 42 million u. s. adults. the symptoms include urinary urgency, frequency and urge incontinence. uroplasty also offers macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. for more information on uroplasty and its products, please visit uroplasty, inc. at
this release includes forward - looking statements intended to qualify for the safe harbor from liability established by the private securities litigation reform act of 1995. these forward - looking statements generally can be identified by phrases such as vision - sciences or its management
believes ,
expects ,
allows ,
anticipates ,
or other words or phrases of similar import. similarly, statements in this release that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward - looking statements. all such forward - looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward - looking statements. other risk factors are detailed in our most recent annual report and other filings with the sec .
this release includes forward - looking statements intended to qualify for the safe harbor from liability established by the private securities litigation reform act of 1995. these forward - looking statements generally can be identified by phrases such as vision - sciences or its management
believes ,
expects ,
allows
,
anticipates ,
or other words or phrases of similar import. similarly, statements in this release that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward - looking statements. all such forward - looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward - looking statements. other risk factors are detailed in our most recent annual report and other filings with the sec .
ms. wolf has an extensive background in finance and the health care industry. before joining vision - sciences, ms. wolf was a managing director at hsbc in its investment banking division where she was a founding member of the firm' s health care group. ms. wolf was responsible for leading the investment banking global medical technology effort, including origination and execution of m & a and corporate finance transactions. while at hsbc, ms. wolf was also a managing director in the firm' s financial sponsors group. prior to hsbc, she was a managing director in the health care group at bear stearns & co. , and before that, at sg cowen and furman selz. ms. wolf holds an m. b. a. from harvard business school and a b. a. from williams college .
ms. wolf has an extensive background in finance and the health care industry. before joining vision - sciences, ms. wolf was a managing director at hsbc in its investment banking division where she was a founding member of the firm' s health care group. ms. wolf was responsible for leading the investment banking global medical technology effort, including origination and execution of m & a; and corporate finance transactions. while at hsbc, ms. wolf was also a managing director in the firm' s financial sponsors group. prior to hsbc, she was a managing director in the health care group at bear stearns & co. , and before that, at sg cowen and furman selz. ms. wolf holds an m. b. a. from harvard business school and a b. a. from williams college .
except for the historical information provided, the matters discussed in this release include forward - looking statements for the purposes of the safe harbor protections under the private securities litigation reform act of 1995. these forward - looking statements generally can be identified by phrases such as vision - sciences or its management
believes ,
expects ,
allows ,
anticipates ,
or other words or phrases of similar import. similarly, statements in this release that describe our business strategy, outlook, objectives, plans, intentions, or goals are also forward - looking statements. all such forward - looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those in forward - looking statements. other risk factors are detailed in our most recent annual report and other filings with the securities and exchange commission. we do not assume any obligation to update any forward - looking statements as a result of new information or future events or developments .
this press release includes forward - looking statements. these forward - looking statements generally can be identified by the use of words such as
anticipate ,
expect ,
plan ,
could ,
may ,
will ,
believe ,
estimate ,
forecast ,
goal ,
project ,
and other words of similar meaning. forward - looking statements in this press release include, but are not limited to, statements about the benefits of the transaction; expected revenue growth rates; the expected timing of the completion of the transaction; and the combined company' s plans, objectives, expectations and intentions with respect to future operations, products and services. each forward - looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. applicable risks and uncertainties include, among others, uncertainties as to the timing of the transaction; uncertainties as to whether uroplasty shareholders and vision - sciences shareholders will approve the transaction; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of either company' s control; the failure to realize synergies and cost - savings from the transaction or delay in realization thereof; the businesses of uroplasty and vision - sciences may not be combined successfully, or such combination may take longer, be more difficult, time - consuming or costly to accomplish than expected; operating costs and business disruption following completion of the transaction, including adverse effects on employee retention and on each company' s respective business relationships with third parties; transaction costs; actual or contingent liabilities; the adequacy of the combined company' s capital resources; and the risks identified under the heading
risk factors
in uroplasty' s annual report on form 10 - k, for the fiscal year ended
please check your spelling. try our suggested matches or see results in other tabs .
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
the spo profiles may contain historical records. please visit the latest spos for the most recent information .
unless otherwise indicated in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, including payment of expenses, working capital and repayment, in whole or in part, of outstanding indebtedness under our amended and restated loan agreement with lewis c. pell, the chairman of our board of directors (the “loan agreement”) dated as of september 30, 2011, and to otherwise meet the company’s liquidity needs. at this time, we have not determined the specific uses of any offering proceeds, or the amounts we plan to spend on any particular use or the timing of such expenditures. pending application of the net proceeds from any particular offering, we intend to invest such proceeds in short - term, interest - bearing, investment - grade securities. subject to the terms of the loan agreement, we may borrow an aggregate of up to $ 10 million, of which $ 8. 0 million (in accrued interest and principal) is outstanding as of the date of this prospectus. under the loan agreement, we are required to apply (i) 100% of the net proceeds from the sale of equity to a third - party to the amounts outstanding up to $ 5 million and (ii) (a) the applicable percentage (defined below) times (b) the amount of such proceeds in excess of $ 5 million, to repay outstanding amounts under the loan agreement. “applicable percentage” means 20% upon receipt by the company of $ 5 million of net proceeds beyond the initial $ 5 million in net proceeds. this percentage increases on a straight line basis up to 100% upon receipt of cumulative net proceeds to the company of at least $ 15 million. each time we issue securities, we will provide a prospectus supplement that will contain information about how we intend to use the proceeds from each such offering. we cannot guarantee that we will receive any proceeds in connection with any offering hereunder because we may choose not to issue any of the securities covered by this prospectus .
medical segment: competition we believe that the primary competitive benefits in the medical market for our flexible endoscopes and endosheath technology are safety and effectiveness, the optical quality of our product offering, product reliability, price, physician familiarity with the manufacturer and its products, ease of use and third - party reimbursement policies. our ability to compete is directly affected by several factors, such as our sales and marketing capabilities, our product development and innovation capabilities, our ability to obtain required regulatory clearances, our ability to protect the proprietary technology which our products are based upon, our manufacturing skills and our ability to attract and retain skilled employees. our current and future product lines face global competition, primarily from companies such as olympus, pentax, and karl storz. some of our competitors and some potential competitors may have greater financial resources, sales and marketing personnel and capabilities, research and development, and manufacturing personnel and capabilities than we do. in addition, any company that is able to significantly redesign conventional flexible endoscopes to simplify the disinfection process, or significantly improve the current methods of disinfecting flexible endoscopes, may result in competition for our products. we believe our proprietary endosheath technology platform currently allows us a significant differentiating factor from our competition. currently, all our competitors are selling endoscopes that require elaborate and time - consuming disinfection procedures. - - - industrial segment: competition in our industrial markets, we believe that our over 35 year history of product effectiveness, ease of use, product reliability and competitive pricing are the principal competitive factors to our success. among our competitors are olympus, ge inspection technologies, and karl storz industrial .
edgar® online, a division of donnelley financial solutions. edgar® is a federally registered trademark of the u. s. securities and exchange commission. edgar online is not affiliated with or approved by the u. s. securities and exchange commission .
enter up to 25 symbols separated by commas or spaces in the text box below. these symbols will be available during your session for use on applicable pages .
please note that once you make your selection, it will apply to all future visits to nasdaq. com. if, at any time, you are interested in reverting to our default settings, please select default setting above. if you have any questions or encounter any issues in changing your default settings, please email isfeedback @ urltoken .
you have selected to change your default setting for the quote search. this will now be your default target page; unless you change your configuration again, or you delete your cookies. are you sure you want to change your settings ?
please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first - rate market news and data you' ve come to expect from us .
, where uroplasty' s current headquarters is located. cogentix medical will be led by
endosheath endoscopy, which combines state - of - the - art endoscopic technology with a sterile, disposable microbial barrier, provides practitioners and healthcare facilities with a solution to meet the growing need for safe, efficient, and cost - effective flexible endoscopy. in addition to the combined company' s increased presence in urology, the combination of the two companies will provide a platform for growth in other specialties that currently perform endoscopic procedures in hospitals and physician offices, which represents an addressable market opportunity of over
u. s. eastern standard time. this call can be accessed in three ways :
by telephone: for both
listen - only
participants and those who wish to take part in the question - and - answer portion of the call, the telephone dial - in number in the u. s. is (888) 806 - 6230. for participants outside the u. s. , the dial - in number is (913) 312 - 0398. the access code for all callers is 2077980 .
. the dial - in number for u. s. participants is (888) 203 - 1112. for participants outside the u. s. , the replay dial - in number is (719) 457 - 0820. the replay access code for all callers is 2077980 .
investors are urged to read the joint proxy statement / prospectus when it becomes available, because it will contain important information .
copyright © 2018 pr newswire association llc. all rights reserved. a cision company .
html public
- / / w3c / / dtd xhtml + rdfa 1. 0 / / en
urltoken
enter your email address and name below to subscribe to any of our free e - newsletters .
sign up for a free crunchbase account to follow and track organizations you care about .
descriptive keyword for an organization (e. g. saas, android, cloud computing, medical device )
this field describes an organization' s most recent funding status (e. g. early stage venture, late stage venture, m & a )
last funding round type (e. g. series a, seed, private equity )
transaction name: auto - generated name of transaction (e. g. angel - uber )
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
this no - sedation method is a viable first line approach in diagnosing diseases of the esophagus. the lack of a need for sedation eliminates the risks and complications associated with sedation and physicians should be discussing this alternative to traditional endoscopy with their patients ,
stated howard siegel, m. d. , founding partner at manhattan internal medicine associates, p. c .
howard zauberman, president and chief executive officer, is available for in - person meetings or phone interviews. please contact mitch kayden at (845) 709 - 5607 or mkayden @ urltoken for more information or to set up an interview .
© 1985 - 2018 biospace. com. all rights reserved. powered by madgex job board software
distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems .
globenewswire is one of the world' s largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public .
we use cookies on this site to enable your digital experience. by continuing to use this site, you are agreeing to our cookie policy. close
data on cases, clients, outside counsel and individual attorneys collected from active federal civil cases. reflects only recently published court data; not intended to be exhaustive. not responsible for errors in court dockets .
to view all the results and drill down deeper, take a free trial now .
gilead' s portfolio of products and pipeline of investigational drugs includes treatments for hiv / aids, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions .
our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for hiv infection available in a once - daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring hiv infection in certain high - risk adults .
collaborations of all kinds – with partners in science, academia, business and local communities – are central to our work. partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible .
gilead was founded in 1987 in foster city, california. since then, we have grown to become one of the world’s largest biopharmaceutical companies, with more than 10, 000 employees across six continents .
at gilead we are inspired by the opportunity to address unmet medical needs for patients living with life - threatening diseases around the world .
© 2009 - 2018 gilead. all rights reserved. terms of use | privacy statements | cookie statement
the origins of the institute for psychological research and application (ipra) can be traced back to 1981. in 1981 an institute designed to provide consulting and research services to local and national organizations was created in the bgsu department of psychology. this institute was originally named the institute for organizational research and development (iord). in 1987, it was decided that the focus of iord was too narrowly defined and did not involve faculty from across the psychology department or the university. therefore, the department proposed to expand the mission of iord in its application for a state of ohio academic challenge award. the industrial / organizational psychology program received this competitive award in 1989. as a result, the name iord was changed to ipra, and the institute became a broader - based organization open to intra and inter - departmental collaborative efforts so as to address and meet a diverse set of client needs for professional services. the goals of ipra are to :
since our inception, we have worked with a great number of clients. here is a partial list of our clients .
bgsu offers alternative versions of all of its pages for our users. you can select the high - contrast version below to persist throughout your bgsu website experience .
bowling green state university (bgsu) has built its website around the standards of the world wide web consortium' s (w3c) hyper text markup language (html) 5 and cascading style sheets (css). the website was built in compliance with the accessibility standards established by section 508 of the rehabilitation act and detailed in section 1194. 22 of the code of federal regulations ,
web - based intranet and internet information and applications
( urltoken) .
bgsu utilizes many webmasters across campus to maintain all of its web properties. keeping the bgsu website in compliance with section 508 is a joint effort between accessibility services, marketing and communications and information technology services. if any page is discovered to be inaccessible, please report it using the above link and we will ensure that the issue is addressed .
to our guests with disabilities, please indicate if you need special services, assistance or appropriate modifications to fully participate in this event by contacting accessibility services, access @ urltoken, 419 - 372 - 8495. please notify us prior to the event .
html public
- / / w3c / / dtd html 4. 01 / / en
urltoken
dr. polsky built an international reputation as an expert in infectious diseases at memorial sloan - kettering cancer center, where he also held the academic title of associate professor of medicine at cornell university medical college. dr. polsky is currently chairman of the department of medicine, chief of the division of infectious diseases, hospital epidemiologist and medical director of the clinical virology laboratory at st. luke' s - roosevelt hospital center in new york city. dr. polsky also serves as the john h. keating sr. professor of clinical medicine at the college of physicians and surgeons of columbia university .
dr. polsky is a graduate of the university of michigan and the wayne state university school of medicine. his post - graduate training in internal medicine was at montefiore medical center and the albert einstein college of medicine in new york city, followed by a fellowship in infectious diseases at memorial sloan - kettering cancer center and cornell university medical college, where he joined the faculty upon completion of his training in 1986, remaining until 1998 .
dr. polsky has been active in clinical investigations in hiv and infections complicating neoplastic disease and aids since the early 1980s. more recently, he has focused on the growing problem of hepatitis c and hepatitis b co - infection with hiv. a member of numerous medical societies in his field of specialty, dr. polsky has published over 200 peer - reviewed book chapters, research studies, clinical abstracts and professional journal articles .
microsoft named satya nadella on tuesday as its new chief executive officer. nadella, who joined the software company 22 years ago, replaces steve ballmer .
british pm: u. s. doesn’t want us to leave eu, putin does
vision sciences inc. ( nasdaq : vsci ) is an international endoscopy product manufacturer and supplier . it was founded in 1987 by lewis c. pell and katsumi oneda and is based in orangeburg , new york . in december 2013 , the company has been selected by 21st century oncology inc. as 21st century ’s preferred vendor of choice and its products will be applied in medical treatment in a variety of therapeutic areas including cancer care . 
vision sciences inc. (nasdaq: vsci) is an international endoscopy product manufacturer and supplier. it was founded in 1987 by lewis c. pell and katsumi oneda and is based in orangeburg, new york. in december 2013, the company has been selected by 21st century oncology inc. as 21st century ’s preferred vendor of choice and its products will be applied in medical treatment in a variety of therapeutic areas including cancer care.
vision sciences inc. (nasdaq: vsci) is an international endoscopy product manufacturer and supplier. it was founded in 1987 by lewis c. pell and katsumi oneda and is based in orangeburg, new york. in december 2013, the company has been selected by 21st century oncology inc. as 21st century ’s preferred vendor of choice and its products will be applied in medical treatment in a variety of therapeutic areas including cancer care.